Phase I Clinical Trial on Intratumoral Administration of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Avelumab and Ipilimumab in Combination With Intravenously Administered Nivolumab

This phase I trial aims at investigating a new combinatorial immunotherapy regimen using intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the PD-L1 blocking mAb avelumab. Concomitantly, nivolumab (a PD-1 blocking mAb) will be administered intravenously.

开始日期2018-01-29

申办/合作机构

Universitair Ziekenhuis Brussel

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的临床结果

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的转化医学

登录后查看更多信息

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的专利（医药）

登录后查看更多信息

项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的文献（医药）

1994-03-01·Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine3区 · 医学

New technique using intraductal ultrasonography for the diagnosis of bile duct cancer.

3区 · 医学

Article

作者: T Furukawa ; M Kuroiwa ; Y Hirooka ; T Katou ; Y Tsukamoto ; Y Naitoh

We investigated the extent to which BDca can be visualized and diagnosed via a percutaneous fistula using IDUS. IDUS was performed in 42 cases, including 15 of normal bile ducts; 12 of choledocholithiasis, and 15 of BDca. The depth of invasion of the BDca was diagnosed with a 93% accuracy rate by visualizing the EP or MA or both. The infiltration of BDca into the surrounding organs was clearly visualized and diagnosed with an accuracy of 100% in the RHA, 93% in the PV, and 93% in the pancreas. These accuracy rates were higher than those obtained by computed tomography or angiography. We believe, therefore, that IDUS should be further studied as a diagnostic modality for staging malignancy in the biliary field.

1990-01-01·Methods in enzymology4区 · 生物学

[78] Probing β-adrenergic receptors

4区 · 生物学

Article

作者: Meier, Kathryn E. ; Ruoho, Arnold E.

The preparation of biotinylated derivatives of propranolol and alprenolol, 2 β-adrenergic antagonists that bind with high affinity to the receptor is described.General methods of detection and quantification of biotin and methods for assessment of binding affinity of the derivatives for β-adrenergic receptors are given.Detailed procedures for the synthesis of cysteaminylalprenolol, biotnylaminododecanoic acid, and biotinyldodecanoylcyeteaminylalprenolol (BDCA) are given.Apparently, it is necessary to introduce a spacer sequence between the 2 ends of bifunctional reagents to allow simultaneous binding of the compounds to both the β-adrenergic receptor and to avidin for binding of both.Apparently, BDCA possesses the optimal characteristics for a bifunctional reagent.

100 项与 Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床1期	比利时	Universitair Ziekenhuis Brussel	2018-01-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03707808 (Pubmed) 人工标引	临床1期	难治性黑色素瘤 CD1c (BDCA-1) \| CD141 (BDCA-3)	8	autologous CD1c (BDCA-1)+ myDC+ ipilimumab + nivolumab	構積壓願獵觸艱餘獵觸(築鏇衊選鏇鬱網構憲繭) = 窪廠鑰築願艱顧遞遞膚鏇窪鏇獵壓壓衊顧選蓋 (範夢襯齋夢膚衊廠糧構 ) 更多	积极	2024-01-11
NCT03707808 (SITC2022) 人工标引	临床1期	BRAF V600 突变阳性黑色素瘤 BRAF V600	8	CD1c (BDCA-1)+/CD141 (BDCA-3)+ myDC(Universitair Ziekenhuis Brussel)+nivolumab+ipilimumab	窪積選鹹積製糧願醖鬱(繭製齋築鑰艱淵鑰齋獵) = 淵齋鏇膚簾夢繭憲範願餘遞願醖選蓋糧鑰獵鏇 (膚鑰蓋願襯夢築鹽艱衊, 5.193 ~ 15.007) 更多	积极	2022-11-01
NCT03707808 (ASCO2019) 人工标引	临床1期	HR阳性/HER2低表达实体瘤二线	6	ipilimumab+Avelumab+Nivolumab+Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells	鑰餘構艱遞夢顧願鹹窪(鹹鹽顧鑰範醖製製齋願) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt 構簾蓋積構網築壓鏇鬱 (鏇壓築廠鬱襯淵選淵顧 ) 更多	积极	2019-05-31